Heterocyclic Compounds Lowering Blood RBP4 for Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds fail to effectively lower blood Retinol Binding Protein 4 (RBP4) concentrations, which are associated with insulin resistance and diabetes, limiting their therapeutic potential for lifestyle-related diseases.
Innovation Solution
Development of specific heterocyclic compounds represented by formula (I) or their salts/prodrugs, which inhibit the binding of RBP4 and retinol, thereby preventing the formation of a complex with Transthyretin, leading to reduced RBP4 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current compounds are used to lower blood RBP4 concentrations, then some therapeutic effect is achieved, but the RBP4-lowering action is insufficient for effective diabetes treatment
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of retinoid compounds through specific substitutions at defined positions (R1, R2, R3, R4, R5, R6, R7, R8) with various groups including hydrogen, halogen, alkyl, alkoxy, and heterocyclic groups. These structural parameter changes enhance the compounds' ability to inhibit RBP4-TTR binding, thereby achieving superior RBP4-lowering action and reliable therapeutic effectiveness for diabetes treatment.
2Quantity of substance
If fenretinide is used to inhibit RBP4-retinol binding, then blood RBP4 concentration is lowered, but the compound lacks sufficient selectivity and potency for optimal therapeutic use
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions on the retinoid molecular structure. Each position (R1-R8) can be independently substituted with specific groups to optimize local interactions with the RBP4 binding site. This localized modification enhances binding inhibition specificity while maintaining the ability to lower blood RBP4 concentration effectively.
3Ease of manufacture
If a compound structure is simplified for ease of synthesis, then manufacturing becomes easier, but the RBP4-lowering activity and therapeutic potential are reduced
Solution Approach 1:
The patent applies segmentation by dividing the complex retinoid molecule into distinct functional regions with specific substitutable positions (R1-R8). This modular structure allows independent optimization of each position to balance synthetic accessibility with biological activity. The segmented approach enables systematic structure-activity relationship studies while maintaining ease of manufacture through standardized substitution patterns.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate a superior RBP4-lowering action, providing a prophylactic or therapeutic agent for diabetes and related conditions by improving insulin sensitivity and correcting hyperglycemia.
Implementation Method 1
compounds represented by formula (I) or their salts/prodrugs, which inhibit the binding of RBP4 and retinol, thereby preventing the formation of a complex with Transthyretin
Data Source
AI summary
The present invention relates towherein each symbol is as defined in the specification. The compound of the present invention has a superior RBP4-lowering action, and is useful as a medicament for the prophylaxis or treatment of disease and condition mediated by increased RBP4.